Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses

WJ Song, CKM Hui, JH Hull, SS Birring… - The Lancet …, 2021 - thelancet.com
Cough is one of the most common presenting symptoms of COVID-19, along with fever and
loss of taste and smell. Cough can persist for weeks or months after SARS-CoV-2 infection …

[HTML][HTML] From purines to purinergic signalling: molecular functions and human diseases

Z Huang, N Xie, P Illes, F Di Virgilio, H Ulrich… - … and Targeted Therapy, 2021 - nature.com
Purines and their derivatives, most notably adenosine and ATP, are the key molecules
controlling intracellular energy homoeostasis and nucleotide synthesis. Besides, these …

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two …

LP McGarvey, SS Birring, AH Morice, PV Dicpinigaitis… - The Lancet, 2022 - thelancet.com
Background Gefapixant is an oral P2X 3 receptor antagonist that has previously shown
efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore …

Update of P2X receptor properties and their pharmacology: IUPHAR Review 30

P Illes, CE Müller, KA Jacobson… - British Journal of …, 2021 - Wiley Online Library
The known seven mammalian receptor subunits (P2X1–7) form cationic channels gated by
ATP. Three subunits compose a receptor channel. Each subunit is a polypeptide consisting …

[HTML][HTML] Chronic cough: new insights and future prospects

A Morice, P Dicpinigaitis, L McGarvey… - European Respiratory …, 2021 - Eur Respiratory Soc
Chronic cough is defined in adults as a cough that lasts for≥ 8 weeks. When it proves
intractable to standard-of-care treatment, it can be referred to as refractory chronic cough …

[HTML][HTML] Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study

A Morice, JA Smith, L McGarvey… - European …, 2021 - Eur Respiratory Soc
Background ATP acting via P2X3 receptors is an important mediator of refractory chronic
cough (RCC). This phase 2a double-blinded crossover study assessed the safety …

A wearable tele-health system towards monitoring COVID-19 and chronic diseases

W Jiang, S Majumder, S Kumar… - IEEE Reviews in …, 2021 - ieeexplore.ieee.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic
since early 2020. The coronavirus disease 2019 (COVID-19) has already caused more than …

Animal models of pain: diversity and benefits

C Abboud, A Duveau, R Bouali-Benazzouz… - Journal of neuroscience …, 2021 - Elsevier
Chronic pain is a maladaptive neurological disease that remains a major health problem. A
deepening of our knowledge on mechanisms that cause pain is a prerequisite to developing …

Validation of a visual analog scale for assessing cough severity in patients with chronic cough

A Martin Nguyen, ED Bacci, M Vernon… - Therapeutic …, 2021 - journals.sagepub.com
Introduction: Patients with chronic cough experience considerable burden. The cough
severity visual analog scale (VAS) records patients' assessment of cough severity on a 100 …

[HTML][HTML] Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers

AJ Davenport, I Neagoe, N Bräuer, M Koch… - Scientific Reports, 2021 - nature.com
Abstract ATP-dependent P2X3 receptors play a crucial role in the sensitization of nerve
fibers and pathological pain pathways. They are also involved in pathways triggering cough …